51
The 10 th International Congress on SLE Buenos Aires, Argentina Neuro-psychiatric SLE Leonor A. Barile-Fabris, MD, PhD Professor of Rheumatology Chair, Rheumatology Department Centro Médico Nacional Siglo XXI Mexico City, Mexico

Lupus neuropsiquiatria

Embed Size (px)

DESCRIPTION

Leonor A. Barile-Fabris, MD, PhD Professor of Rheumatologo Chair, Rheumatology Department Centro Médico Nacional Siglo XXI Mexico City, Mexico

Citation preview

Page 1: Lupus neuropsiquiatria

The 10th International Congress on SLEBuenos Aires, Argentina

Neuro-psychiatric SLE

Leonor A. Barile-Fabris, MD, PhD Professor of Rheumatology

Chair, Rheumatology Department Centro Médico Nacional Siglo XXI

Mexico City, Mexico

Page 2: Lupus neuropsiquiatria

Key points

NP manifestations have been increasingly recognized.

Both attribution and diagnosis remain clinical challenges.

Selection of optimum treatment is complex due to scarce and heterogeneous clinical data.

Page 3: Lupus neuropsiquiatria

Key issues in SLE patients with neuropsychiatric manifestations

EULAR Task force on SLE- Evidence and expert-based answers

• Who is at risk to develop NPSLE?

• Is NPSLE common?

• When to suspect NPSLE?

• How can I attribute a NP event to SLE?

• How do I treat NPSLE?

Bertisas GK.Nat Rev Rheumatol.2010:6;1-10

Page 4: Lupus neuropsiquiatria

Key points

NP symptoms are present in approximately 20 to 50% of SLE patients, frequently within the first 2 years.

These symptoms are primarily associated with a poor HRQoL and an increase in functional impairment, leading to unemployment in some cases.

Mild manifestations are common and include headache, anxiety, depression, and cognitive deficit. These, however, are not normally related to the disease.

Source: Bertisas GK. Nat Rev. Rheumatol. 2010:6;1-10.

Page 5: Lupus neuropsiquiatria

Neuropsychiatric SLE – General statements

1. When do they occur?

-May precede, coincide, or follow the diagnosis of SLE but commonly (40-50%) occur within the first year after SLE diagnosis,

-Usually (50-60%) in the presence of generalized disease activity (B).

2. Cumulative incidence of neuropsychiatric manifestations:

- common (10-20%): cerebrovascular disease, seizures

- relatively uncommon (3-10%): severe cognitive dysfunction, major depression, acute confusional state and peripheral nervous disorders

- rare (<3%): psychosis, myelitis, chorea, cranial neuropathies, aseptic meningitis (B)

EULAR Recommendations for the Management of Neuropsychiatric SLE

eular

Bertisas GK. Ann Rheum Dis: 69.2074-82

Page 6: Lupus neuropsiquiatria

NP events at the time of diagnosis

Hanly JG. Ann Rheum Dis 2101;3:529-35.

Page 7: Lupus neuropsiquiatria

NP Manifestations in 88 SLE patients at the Centro Médico Nacional “La Raza”, Mexico City

Manifestation Number

Seizures 32

Delirium 21

Stroke 15

Pheripheral neuropathy 12

Optic neuritis 10

Transverse myelitis 4

Barile et al. Lupus 1988;7:S 107

Page 8: Lupus neuropsiquiatria

Seizures 99 30.9

Headeache 54 16.8

Psychosis 49 15.3

Delirium 47 14.6

Stroke 34 10.6

Sensitive neuropathy 33 10.3

Motor neuropathy 31 9.6

Coma 10 3.13

Aseptic meningitis 7 2.19

Transverse myelitis 7 1.7

Chorea 5 1.5

Ataxia 4 1.2

Pseudo tumor cerebri 2 0.63

Organic brain syndrome 2 0.63

GLADEL

Barile et al. Lupus 1998 (Suppl);7:53

Page 9: Lupus neuropsiquiatria

Differing prevalences in LSE

Highly heterogeneous clinical manifestations.Some are not specific or “subclinical”.Manifestations may be present despite the

absence of other disease activity signs.Attribution is difficult to establish.There might be differences between inception

and survival cohorts.

Page 10: Lupus neuropsiquiatria

Bertisas GK.Nat Rev Rheumatol.2010:6;1-10

Page 11: Lupus neuropsiquiatria

Bertisas GK.Nat Rev Rheumatol.2010:6;1-10

Page 12: Lupus neuropsiquiatria

Neuropsychiatric SLE – General statements

4. Diagnostic work-up

a) In SLE patients with new or unexplained symptoms or signs suggestive of neuropsychiatric disease, initial diagnostic work-up should be similar to that in non-SLE patients presenting with the same manifestations (D).

b) Depending upon the manifestation, this may include lumbar puncture and CSF analysis (primarily to exclude CNS infection), EEG, neuropsychological assessment of cognitive function, nerve conduction studies, and neuro-imaging (MRI) to assess brain structure and function (D).

c) The recommended MRI protocol (brain and spinal cord) includes conventional MRI sequences (T1/T2 FLAIR), diffusion-weighted imaging (DWI), and gadolinium-enhanced T1 sequences (B).

EULAR Recommendations for the Management of Neuropsychiatric SLE

eular

Bertisas GK. Ann Rheum Dis: 69.2074-82

Page 13: Lupus neuropsiquiatria

MRI white-matter lesions in NPSLE

• ↑ signal in Τ2 / FLAIR

• Localized in subcortical and periventricular white matter and frontal-parietal lobe (70–80%)

• Prevalence 50–60% of all patients with NPSLE …but 18–40% of non-NPSLE

…no correlation with a particular NP syndrome

• Cerebral atrophy, number and size of WML and cerebral infarcts correlate with severity of cognitive dysfunction

In young SLE patients new MRI WMLs (especially if ≥5, ≥6-8mm, and bilateral may suggest active NPSLE

Page 14: Lupus neuropsiquiatria

Case 1

2007 SLE: Arthritis, cutaneous involvement, serologic criteria.

ANA 1:280 C4 3 C3 55

2009 Arthritis, skin.

2010 Arthritis, Raynaud, digital vasculitis.

Methilprdnisolone 3grIV Cy single dose

Abril 2010Anxiety, insomnia, mood disorders.CAT and MRI: Normal. CSF:NormalSteroidal psicoisis Ketiapine 200mg, Prednisone 35mg, Sertraline 50mg MMF 2 gr /d.

2011 SLEDAI 0 (low complement levels) slow prednisone tappering and MMF.

Regional hospital : MMF 500mg d.

Page 15: Lupus neuropsiquiatria

24/02/13:Seizures.Increased reflexes.DFH Levertiracetam, Metilprednisolone 3 gr.

03/03/13:Seizures.Increased reflexes.DFH Levertiracetam, Metilprednisolone 3 gr.Abnormal movements.Topiramate and lumbar puncture.

06/03/13:Anxiety-depression disorder.

Case 1 (Readmission)

Page 16: Lupus neuropsiquiatria

IRM

Page 17: Lupus neuropsiquiatria

Identifying differential diagnosis

Embolic infarct.Opportunistic infection.Brain abscess.NP SLE.Brain tumor.

Page 18: Lupus neuropsiquiatria

MRI Diagnosis

Radiology: Infarcts (embolus), cortical, in two different territories, restricted diffusion, low ADC.

Neurology: Opportunistic infection (toxoplasmosis) vs. brain abscess (headache, fever, seizures).

Page 19: Lupus neuropsiquiatria

Cardioembolic infarct

NP SLE

Abscess

Tumor

CSF:Cels 0, RC 10, C 100%.Prot25.2 mg/dl, Gluc42 mg/dl, Cl 127 mEq/L. ANA (-), C3 y C4 0, Anti DNA 8.9, aCL 2.0

Gramm (-).Cultive (-)

Brain gammagram Taliium 201 and Gallium 67: normal.

.

IV Cy.

Case 1: results

TE echocardiogram: Normal

Page 20: Lupus neuropsiquiatria

MRI in NP SLE

Multiple white matter lesions.Cerebral infarction.Cerebral hemorrhage.Venous sinus thrombosis.Atrophic changes.Spinal cord disease.

Lupus 2003;12:891

Page 21: Lupus neuropsiquiatria
Page 22: Lupus neuropsiquiatria
Page 23: Lupus neuropsiquiatria
Page 24: Lupus neuropsiquiatria

Saggital T1 image: Clot in the Stright sinus

Page 25: Lupus neuropsiquiatria
Page 26: Lupus neuropsiquiatria

Take-home messages,case 1

There is not such thing as a typical MRI in neurolupus.

Differential diagnosis comprises a wide range of causes.

Page 27: Lupus neuropsiquiatria
Page 28: Lupus neuropsiquiatria
Page 29: Lupus neuropsiquiatria

Prognosis and treatment

Page 30: Lupus neuropsiquiatria

Prognosis

Poor prognosis factors:• Caucasians?• Active disease• aRO, LA, IgG aCl.

Rheumatology 2004; 43:1555-1560.

Page 31: Lupus neuropsiquiatria

Prognosis in 2 referral hospitals in Mexico City

71%

29%

improvement no response

Page 32: Lupus neuropsiquiatria

Poor prognosis, cont’d.

Male gender.neuroSLICC ≥1 p = 0.0001.↑antiDNA p= 0.21.Low complement levels p= 0.05.↑ESR p= 0.036.

Page 33: Lupus neuropsiquiatria

Poor prognosis factors

Consolidation analysis:

Normal ESR and complement: 85.7% improved.Low complement and high ESR : 69.2% worsened.P= 0.001

Page 34: Lupus neuropsiquiatria

Treatment

Barile L. Reumatol Clin. 2005;1 Supl 2: S42-5

Page 35: Lupus neuropsiquiatria

5. Therapy

a) Corticosteroids and immunosuppressive therapy are indicated for neuropsychiatric manifestations felt to reflect an immune/inflammatory process (acute confusional state, aseptic meningitis, myelitis, cranial and peripheral neuropathies, and psychosis) following exclusion of non-SLE related causes (A, D).

b) Anti-platelet/anti-coagulation therapy is indicated when manifestations are related to anti-phospholipid antibodies, particularly in thrombotic cerebrovascular disease (A, D).

c) The use of symptomatic therapies (e.g. anticonvulsants, antidepressants) and the treatment of aggravating factors (e.g. infection, hypertension and metabolic abnormalities) should also be considered (D).

d) Anti-platelet agents may be considered for primary prevention in SLE patients with persistently positive, moderate or high, anti-phospholipid antibody titers (D).

EULAR Recommendations for the Management of Neuropsychiatric SLE

eular

Neuropsychiatric SLE – General statements

Page 36: Lupus neuropsiquiatria

• Induction Metilprednisolone (MP) 1 g/d for 3 d.

• MP 1 g/d por 3 d, monthly for 4 m, then bimonthly for 6 m, and subsequently every 3 m for 1 y.

or

• Ciclophosphamide (Cy) 0.75 g/m2 bs monthly for 1 y, and every 3 m for another y.

Ann Rheum Dis 2005;64:620–625.

Page 37: Lupus neuropsiquiatria
Page 38: Lupus neuropsiquiatria

Allocation

Page 39: Lupus neuropsiquiatria

Median monthly values of visual analogue scale ratings for changes in muscular strenght in NP and TM patients

0= No changes from basal conditions; 10= the best possible improvement

P=0.04

Page 40: Lupus neuropsiquiatria

MPDCFM

Seizures

Page 41: Lupus neuropsiquiatria

Average prednisone intake/ day

Page 42: Lupus neuropsiquiatria

Response to treatment

Response MPD CY

Failure 7 1

Improvement 11 18

p

<0.003

<0.05

Page 43: Lupus neuropsiquiatria

Trevisani et al Cochrane 2008

Page 44: Lupus neuropsiquiatria

Case: Female, 62 years old.

2001: Optic Neuritis in right eye.2010: Non Hodgkin lymphoma, QxTx RxRx. May 2010: Optic Neuritis in left eye.Hypotiroidism. ANA 1:640 H, lymphopenia,

leukopenia, Neurolupus: Pdn 50mg/d and Mycophenolate.

Oct 3 2010: Hyperstetic sensitive level C5 and T7, medular discharges, hyporeflexia.

Page 45: Lupus neuropsiquiatria

Oct 3 2010: Hyperstetic sensitive level C5 and T7, medular discharges, hyporeflexia.

MRI: Hyper intensity with T1 enhancement, suggestive of longitudinal myelopathyFrom C2 to T12 with high activity in neuro-imaging

Page 46: Lupus neuropsiquiatria
Page 47: Lupus neuropsiquiatria
Page 48: Lupus neuropsiquiatria

Selecting treatment

• IV MP• Oral prednisone and high dose MMF• IV Cy• Plasmaphereis• IV MP and IV Cy• Others?

Page 49: Lupus neuropsiquiatria

MP 5 gPdn 50 mg/d

Partial improvement in sensitivity. Paraplegia. Acute confusional syndrome. Delirium. IV Cy 700mg.

Currently: 6 pulses Partial recovery Sensitivity fully recovered Motor capacity 30% recovery

Page 50: Lupus neuropsiquiatria

Take-home messages: Case 2

Despite published evidence, response to treatment even within the same clinical manifestation may be heterogeneous.

Transverse myelopathy has a better prognosis than longitudinal myelopathy.

Page 51: Lupus neuropsiquiatria

Final considerations

There are different clinical subgroups in neurolupus.

Etiopathogenic mechanisms might be different, but they all seem to be related to vascular endothelium.

NP SLE has a profound impact in prognosis, HRQoL and damage.